MTOR and glioblastoma: Besides the tyrosine kinase inhibitors, correlation between in silico predictions and experimental results for the 8 patient-derived GBM cell lines was also tested for drugs such as pitavastatin (HMG CoA reductase inhibitor), everolimus (mTOR inhibitor), celecoxib (COX2 inhibitor) and bortezomib (proteasome inhibitor) (Figure 6 A-H).